Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

1. AUPH reports Q4 earnings of $0.01, improving from a $0.19 loss last year. 2. Sales reached $59.9 million, up 33% year-over-year, aligning with consensus. 3. LUPKYNIS net sales were $57.6 million, a 36% increase. 4. 2024 net product sales expected at $216.2 million, within guidance. 5. Stock dropped 6.35% to $7.45 post-earnings announcement.